GINA Guidelines for Asthma Diagnosis
Asthma diagnosis requires objective testing with spirometry demonstrating reversible airflow obstruction or bronchial hyperresponsiveness—symptoms alone are insufficient and strongly discouraged for diagnosis. 1
Core Diagnostic Principle
Never diagnose asthma based on symptoms alone. This is a strong recommendation against symptom-only diagnosis, supported by moderate quality evidence 1. While recurrent wheeze, cough, and breathing difficulty are key features of asthma, they lack the specificity needed for definitive diagnosis 1.
Diagnostic Algorithm
Step 1: Clinical Assessment
- Wheeze is the most important symptom—specifically recurrent reported wheeze or wheeze on auscultation 1
- Wheeze is defined as a soft polyphonic noise or whistling sound heard mainly during expiration 1
- Critical caveat: Chronic cough (>4 weeks) as the only symptom makes asthma unlikely and requires investigation for alternative diagnoses 1
- Symptoms vary over time and may respond to bronchodilator treatment 1
Step 2: Spirometry (First-Line Objective Test)
- Perform spirometry to document airflow obstruction 1, 2
- Look for FEV1 or FEV1/FVC less than lower limit of normal (LLN) and/or <80% predicted 1
- Important limitation: Normal spirometry does not exclude asthma; abnormal spirometry does not confirm it 1
Step 3: Bronchodilator Reversibility (BDR) Testing
- Positive BDR: ≥12% AND ≥200 mL improvement in FEV1 after bronchodilator 1
- BDR testing can be performed even with normal baseline spirometry if clinical suspicion is strong 1
- If BDR is negative (<12% and/or <200 mL), refer for specialist opinion 1
Step 4: FeNO Testing
- Fractional exhaled nitric oxide (FeNO) should be performed when initial spirometry and BDR testing fail to confirm diagnosis 1
- FeNO ideally should be performed before spirometry, and many clinics perform both tests together 1
- Elevated FeNO supports airway inflammation consistent with asthma 1
Step 5: Bronchial Challenge Testing (If Diagnosis Remains Uncertain)
- Direct bronchial challenge testing with methacholine or indirect challenge testing (treadmill or bicycle) should be performed when asthma diagnosis cannot be confirmed with other objective tests 1
- Peak expiratory flow variability can be used as an inferior alternative where challenge testing is unavailable 1
Treatment Trial as Diagnostic Tool
If initial objective tests fail to confirm diagnosis:
- Initiate anti-inflammatory therapy with inhaled corticosteroids according to GINA step 2 or 3, depending on symptom severity 1
- Demonstrate and check inhaler technique; prescribe age-appropriate spacer devices 1
- Reassess after treatment: Improvement in FEV1 >7% may be considered significant 1
- Watchful waiting with repeat testing is appropriate in children with normal spirometry, especially when symptomatic 1
- Reduce treatment after 6-12 months of disease stability 1
Key Diagnostic Pitfalls
- Do not rely on PEFR variability as primary diagnostic tool—evidence supporting this test in children is weak, and the cut-off differs from other guidelines (12% vs 20%) 1
- Recognize that asthma is heterogeneous—not all features (reversible obstruction, inflammation, hyperresponsiveness) are present simultaneously in every patient 1
- Language and cultural barriers: The term "wheeze" is poorly understood and has no equivalent in many languages; parents often describe stridor and rattles as wheeze 1
- Age considerations: Young children may describe abdominal pain due to difficulty localizing symptoms to the lungs 1
Updated GINA Recommendations (2024)
The GINA 2024 guidelines include a revised diagnostic flow chart emphasizing alternative tools like peak flow meters in resource-limited settings 3. The guidelines address challenges related to bronchodilator reversibility interpretation and FEV1/FVC ratios 3. All adults, adolescents, and most children with asthma should receive ICS-containing therapy to reduce severe exacerbation risk, not SABA alone 2, 4.